ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

triptorelin

Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.

Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.

Drug pageTriptorelin: every studyMany companies study it; this page follows only the 20 they lead. All 102 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 23, 201220 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen130 open or runningphase 4since Aug 23, 2012Dec 21, 2006none ahead
Debiopharmits history only30 open or runningphase 3since Sep 11, 2008Sep 11, 2008none ahead
Foresee Pharmaceuticalsits history only20 open or runningphase 3since Jan 22, 2025Jan 22, 2025none ahead
AbbVieits history only10 open or runningphase 4since Jul 9, 2010Jul 9, 2010none ahead
Pharmatechits history only10 open or runningphase 4since May 8, 2012May 8, 2012none ahead

Also a collaborator on its studies: QPS and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ipsen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2006First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT00415246 · 100 enrolled · Belgium, France, Latvia and more
  2. Mar 7, 2007Phase 2 study in Prostatic NeoplasmsNCT00444639 · 25 enrolled · Netherlands
  3. Nov 27, 2007Phase 3 study in Puberty, PrecociousNCT00564850 · 37 enrolled · France
  4. May 28, 2009Phase 3 study in Puberty, PrecociousNCT00909844 · 35 enrolled · France
  5. Nov 24, 2009Phase 3 study in Prostatic NeoplasmsNCT01020448 · 339 enrolled · Belgium, Denmark, France and more
  6. Dec 8, 2010Phase 2 study in Prostatic NeoplasmsNCT01257425 · 109 enrolled · Germany
  7. Jun 14, 2011Phase 2 study in Prostatic NeoplasmsNCT01374087 · 32 enrolled · Spain
  8. Aug 23, 2012Phase 4 study in Prostatic NeoplasmsNCT01673984 · 27 enrolled · United Kingdom
  9. Oct 24, 2012Phase 3 study in Prostatic NeoplasmsNCT01715129 · 126 enrolled · Bulgaria, France, Latvia and more
  10. Dec 17, 2012Phase 4 study in Prostatic NeoplasmsNCT01753297 · 226 enrolled · China, Russian Federation
  11. Jan 29, 2021Phase 3 study in Puberty, PrecociousNCT04736602 · 32 enrolled · China
  12. Aug 9, 2021Phase 3 study in Puberty, PrecociousNCT05029622 · 66 enrolled · China
  13. Jun 17, 2022Phase 3 study in Prostatic NeoplasmsNCT05458856 · 147 enrolled · Belgium, Czechia, France and more

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GoserelinruleAstraZenecaphase 414

Studies

All 13 Ipsen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05458856Prostatic Neoplasms · Belgium, Czechia, France and more3CompletedJul 8, 2024147
NCT05029622Puberty, Precocious · China3CompletedAug 21, 202266
NCT04736602Puberty, Precocious · China3CompletedFeb 9, 202232
NCT01753297Prostatic Neoplasms · China, Russian Federation4CompletedSep 9, 2019226
NCT01715129Prostatic Neoplasms · Bulgaria, France, Latvia and more3CompletedOct 2013126
NCT01673984Prostatic Neoplasms · United Kingdom4TerminatedFeb 201427
NCT01374087Prostatic Neoplasms · Spain2TerminatedDec 201432
NCT01257425Prostatic Neoplasms · Germany2CompletedFeb 2012109
NCT01020448Prostatic Neoplasms · Belgium, Denmark, France and more3CompletedNov 2011339
NCT00909844Puberty, Precocious · France3CompletedApr 201535
NCT00564850Puberty, Precocious · France3CompletedOct 201037
NCT00444639Prostatic Neoplasms · Netherlands2TerminatedFeb 200825
NCT00415246Prostatic Neoplasms · Belgium, France, Latvia and more3Terminated100

How it is read

Names in the registry

  • “Triptorelin embonate 22.5 mg”, 2 entries
  • “Triptorelin (Decapeptyl®)”, 2 entries
  • “Decapeptyl® SR 22.5mg”, 1 entry
  • “Triptorelin Mesylate”, 1 entry
  • “FP-014”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.